Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
Article in Medicine (July 2023)
The most recent citing publications are shown below. View all 32 publications that cite this research output on Dimensions.
Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma
Article in Journal of Clinical Pharmacy and Therapeutics (October 2022)
Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
Article in Frontiers in Oncology (June 2022)